LYRA
Lyra Therapeutics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 10 Lyra Therapeutics terminated leases for its Watertown and Waltham fa…
- R Apr 17 Lyra Therapeutics announced it will voluntarily file a Form 25 to de…
- R Apr 17 Lyra Therapeutics terminated its sublease for 23,704 square feet in…
- R Apr 30 Lyra Therapeutics filed a Form 15-12G to voluntarily terminate its S…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q4 2025: 2 added (0 new), 4 trimmed or exited.
- TrendUPTREND
19% above its 50-day average.
Who's buying
13F· Q4 2025| Fund | Move | Value |
|---|---|---|
| CWM, LLC | NEAR_EXIT | — |
| BlackRock, Inc. | ADD | $7.4K |
| UBS Group AG | NEAR_EXIT | $2.1K |
| MORGAN STANLEY | TRIM | $1.0K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $619.00 |
| CITIGROUP INC | NEAR_EXIT | $9.00 |
| CWM, LLC | NEAR_EXIT | — |
| UBS Group AG | DOUBLED | $26.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Aug 2025| Date | Firm | Rating |
|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. REITERATE | Neutral |
| Jun 10, 2025 | HC Wainwright & Co. MAINTAIN | Neutral |
| Mar 14, 2025 | HC Wainwright & Co. REITERATE | Neutral |
| Aug 15, 2024 | Cantor Fitzgerald REITERATE | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| Jun 20, 2024 | Cantor Fitzgerald REITERATE | Overweight |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Smith W Bradford Director | TO ISSUER | 640 sh |
| Apr 1, 2026 | Palasis Maria Principal Executive Officer | TO ISSUER | 2,000 sh |
| Apr 1, 2026 | Cavalier Jason Principal Financial Officer | TO ISSUER | 667 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
3 filings · 1 press release · 0 bullish · 3 bearish- BEARISH 15-12GApr 30, 2026
Lyra Therapeutics filed a Form 15-12G to voluntarily terminate its SEC registration and suspend…
Existing shareholders face loss of SEC-mandated disclosures and likely reduced liquidity as the stock moves further into the OTC market. Monitor for potential delisting from any remaining exchange…
- BEARISH 8-KApr 17, 2026
Lyra Therapeutics terminated its sublease for 23,704 square feet in Waltham, Massachusetts…
The termination suggests Lyra is consolidating or downsizing operations, likely to conserve cash. The $2.1 million termination fee represents a material near-term cash outflow for a small-cap…
- BEARISH PRESS RELEASEApr 17, 2026
Lyra Therapeutics announced it will voluntarily file a Form 25 to delist its stock from Nasdaq…
Traders should anticipate reduced liquidity and wider bid-ask spreads as LYRA moves to the OTC Pink market. The delisting signals financial or operational distress, and the upcoming termination of…
- BEARISH 8-KApr 10, 2026
Lyra Therapeutics terminated leases for its Watertown and Waltham facilities, incurring $3.9…
The termination of long-dated leases at significant cost suggests Lyra is undergoing a major restructuring or winding down operations. Traders should watch for further cost-cutting announcements…
All LYRA filing & press-release reports (4)
- 15-12G reportApr 30, 2026
- 8-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- 8-K reportApr 10, 2026